High-dose immunoglobulin - Life-saving in invasive group a streptococcal infection;Immunglobulin i hög dos - Livräddande vid invasiv grupp A-streptokockinfektion: Rapport om elva fall där tio överlevde

Lakartidningen

Volumn 101, Issue 35, 2004, Pages 2642-2644

  Arnholm, Birgitta ^a   Lundqvist, Anders ^a   Strömberg, Anders ^a,b  

^a Samtliga vid Infektionskliniken   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; CLINDAMYCIN; IMMUNOGLOBULIN G; PENICILLIN G;

ARTICLE; BACTERIAL INFECTION; HUMAN; MORTALITY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 4544340597     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Low DE, Schwartz B, McGeer A. The reemergence of severe group A streptococcal disease: an evolutionary perspective. In: Emerging infections, Vol 7. Washington, DC: ASM Press; 1997. p. 93-123.
2. Strömberg A, Romanus V, Burman L. Outbreak of group A streptococcal bacteremia in Sweden: an epidemiological and clinical study. J Infect Dis 1991;164:595-8.
3. Norrby-Teglund A, Kotb M. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000;49:849-52.
4. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of the pathogenesis in serious group A streptococcal infections in Sweden 1988-1989. J Infect Dis 1992;166:31-7.
5. Eriksson B, Andersson J, Holm SE, Norgren M. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999;180:410-8.
6. Davies DH, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. The Ontario Group A Streptococcal Study Group. N Engl J Med 1996;67:1871-7.
7. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998;27:1428-36.
8. Norrby-Teglund A, Stevens DL. Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis 1998;11:285-91.
9. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:8007.
10. Darenberg J, Ihendyane N, Sjölin J, Aufweber E, Haidi S, Follin P, et al, and the Streptig Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
11. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rational and consensus definition. JAMA 1993;269:390-1.